US drugmakers allegedly collude on generic price hikes
A coalition of 43 attorneys general allege generic drug manufacturers colluded, overcharging US states and consumers billions.
List view / Grid view
A coalition of 43 attorneys general allege generic drug manufacturers colluded, overcharging US states and consumers billions.
The Cleanroom Technology Conference will take place at the National Conference Centre in Birmingham on 21-22 May.
Health Canada has published new guidance for manufacturers of higher-risk 3D-printed medical devices.
Gavi, the Vaccine Alliance has announced support for the expansion of a medical drone network into Ghana.
A new clinical trial will determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
Chemspec Europe 2019 gathers impressive array of industry experts under one roof
A new drug for Huntington disease is found to be safe and lowers levels of the abnormal protein that causes the debilitating disease in patients.
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
Leading international partner to the biopharmaceutical industry Sartorius Stedim Biotech (SSB) has today announced that the new SIMCA® 16 software for multivariate data analytics is available from its subsidiary Sartorius Stedim Data Analytics.
The US Food and Drug Administration (FDA) has approved new treatments for heart disease caused by ATTR-CM in adults.
A filter has been designed to create more exact measurements early in the drug development stage and help move a drug to clinical trials faster.
A new study has found that prices for brand-name prescription drugs averaged 3.2 to 4.1 times higher in the US compared with other countries.
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
Marketing authorisation has been recommended in the EU by an EMA committee for Sixmo (buprenorphine) as a substitution treatment for opioid dependence.